Novel Compound Heterozygous Missense Variants in RPL3L Gene Associated With Neonatal Dilated Cardiomyopathy
American Journal of Medical Genetics Part A · 2026
DOI: 10.1002/ajmg.a.64225 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, 2026. Verfasst von Xianghong Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child H…. Hauptthemen laut MEDLINE: Cardiomyopathy, Dilated, Genetic Predisposition to Disease, Mutation, Missense, Ribosomal Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Dilated cardiomyopathy type 2D (CMD2D) is a rare autosomal recessive disorder characterized by neonatal‐onset severe cardiomyopathy, rapid progression to cardiac decompensation, and high mortality, with heart transplantation being the only life‐saving intervention. Although mutations in RPL3L , a muscle‐specific ribosomal protein gene critical for cardiac and skeletal muscle function, are known to cause CMD2D, this disorder remains genetically and clinically undercharacterized. To date, only 13 patients with RPL3L ‐related CMD2D have been reported, with nearly all of whom are attributed to compound missense mutations. Using whole exome sequencing, we identified an infant with fulminant DCM and severe acute heart failure who carried compound heterozygous RPL3L variants: c.346C>T (p.R116C) and c.605A>G (p.E202G). Histopathological analysis revealed cardiomyocyte death, collagen deposition, disturbed mitochondrial structure, and deregulated sarcomeres. Computational protein modeling demonstrated these mutations induce conformational changes in RPL3L, suggesting potential functional relevance. This case expands the mutational spectrum of CMD2D and emphasizes the need for further genotype–phenotype correlations to elucidate the pathogenesis of this lethal disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiac Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Zhejiang, Hangzhou, China.
- Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China.
- Zhejiang Key Laboratory of Neonatal Diseases, Hangzhou, Zhejiang, China.
- Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Zhejiang, Hangzhou, China.
- Department of Pathology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Zhejiang, Hangzhou, China.
- Department of Cardiac Surgery, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Zhejiang, Hangzhou, China.
ORCID-Profile: Xianghong Zhang, Hongyu Chen, Lan Yu
Förderung
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zhang, X., Wen, T., Chen, H., Jiang, Z., Gu, W., Yuan, W., Li, F., Shi, S., Shu, Q., & Yu, L. (2026). Novel Compound Heterozygous Missense Variants in RPL3L Gene Associated With Neonatal Dilated Cardiomyopathy. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.64225
Vancouver
Zhang X, Wen T, Chen H, Jiang Z, Gu W, Yuan W, et al. Novel Compound Heterozygous Missense Variants in RPL3L Gene Associated With Neonatal Dilated Cardiomyopathy. American Journal of Medical Genetics Part A. 2026. doi:10.1002/ajmg.a.64225
BibTeX
@article{Zhang2026,
author = {Zhang, Xianghong and Wen, Tingting and Chen, Hongyu and Jiang, Ziyi and Gu, Weizhong and Yuan, Weihua and Li, Fengxia and Shi, Shanshan and Shu, Qiang and Yu, Lan},
title = {Novel Compound Heterozygous Missense Variants in RPL3L Gene Associated With Neonatal Dilated Cardiomyopathy},
journal = {American Journal of Medical Genetics Part A},
year = {2026},
doi = {10.1002/ajmg.a.64225}
}
EUVIMED